Ionis Pharmaceuticals (IONS) Ratios
Ionis Pharmaceuticals Ratios
MX:IONS's free cash flow for Q2 2026 was $549.45M. For the 2026 fiscal year, MX:IONS's free cash flow was decreased by $-16.08M and operating cash flow was $565.53M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.83 | 8.47 | 5.90 | 7.07 | 9.75 |
| Quick Ratio | 3.81 | 8.43 | 5.88 | 7.00 | 9.65 |
| Cash Ratio | 0.48 | 0.78 | 0.89 | 0.89 | 3.61 |
| Solvency Ratio | -0.12 | -0.18 | -0.13 | -0.13 | -0.00 |
| Operating Cash Flow Ratio | -0.34 | -1.62 | -0.69 | -0.88 | 0.13 |
| Short-Term Operating Cash Flow Coverage | -0.59 | -53.99 | -5.78 | -36.41 | 8.73 |
| Net Current Asset Value | $ -44.75M | $ 204.97M | $ 38.47M | $ 241.71M | $ 505.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.74 | 0.47 | 0.49 | 0.54 | 0.48 |
| Debt-to-Equity Ratio | 5.35 | 2.41 | 3.76 | 2.39 | 1.62 |
| Debt-to-Capital Ratio | 0.84 | 0.71 | 0.79 | 0.71 | 0.62 |
| Long-Term Debt-to-Capital Ratio | 0.80 | 0.68 | 0.76 | 0.67 | 0.61 |
| Financial Leverage Ratio | 7.20 | 5.11 | 7.73 | 4.42 | 3.38 |
| Debt Service Coverage Ratio | -0.52 | -3.48 | -1.99 | -15.30 | -0.36 |
| Interest Coverage Ratio | -4.22 | -5.25 | -4.34 | -50.50 | -3.23 |
| Debt to Market Cap | 0.19 | 0.24 | 0.18 | 0.22 | 0.29 |
| Interest Debt Per Share | 16.91 | 10.08 | 10.73 | 9.71 | 8.94 |
| Net Debt to EBITDA | -7.89 | -3.32 | -4.47 | -4.80 | -73.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 98.31% | 98.41% | 98.84% | 97.60% | 98.66% |
| EBIT Margin | -32.52% | -53.28% | -32.80% | -42.54% | -3.05% |
| EBITDA Margin | -30.12% | -50.16% | -29.95% | -38.78% | -0.64% |
| Operating Profit Margin | -40.47% | -67.37% | -44.91% | -69.84% | -3.72% |
| Pretax Profit Margin | -40.25% | -65.25% | -42.40% | -43.92% | -3.60% |
| Net Profit Margin | -40.36% | -64.37% | -46.50% | -45.92% | -3.53% |
| Continuous Operations Profit Margin | -40.36% | -64.37% | -46.50% | -45.92% | -3.53% |
| Net Income Per EBT | 100.26% | 98.66% | 109.68% | 104.55% | 98.11% |
| EBT Per EBIT | 99.48% | 96.84% | 94.41% | 62.89% | 96.56% |
| Return on Assets (ROA) | -10.81% | -15.11% | -12.25% | -10.64% | -1.09% |
| Return on Equity (ROE) | -77.90% | -77.15% | -94.72% | -47.08% | -3.71% |
| Return on Capital Employed (ROCE) | -13.93% | -17.63% | -13.92% | -18.46% | -1.27% |
| Return on Invested Capital (ROIC) | -11.96% | -17.34% | -13.63% | -18.40% | -1.25% |
| Return on Tangible Assets | -10.81% | -15.11% | -12.25% | -10.64% | -1.11% |
| Earnings Yield | -3.01% | -8.68% | -5.06% | -5.03% | -0.67% |
| Efficiency Ratios | |||||
| Receivables Turnover | 14.30 | 7.65 | 8.06 | 23.00 | 13.09 |
| Payables Turnover | 0.57 | 0.26 | 0.35 | 0.79 | 0.91 |
| Inventory Turnover | 1.59 | 0.90 | 1.23 | 0.64 | 0.44 |
| Fixed Asset Turnover | 2.61 | 2.75 | 3.24 | 2.30 | 4.13 |
| Asset Turnover | 0.27 | 0.23 | 0.26 | 0.23 | 0.31 |
| Working Capital Turnover Ratio | 0.42 | 0.31 | 0.39 | 0.29 | 0.45 |
| Cash Conversion Cycle | -385.88 | -943.36 | -697.48 | 122.19 | 462.23 |
| Days of Sales Outstanding | 25.52 | 47.72 | 45.31 | 15.87 | 27.88 |
| Days of Inventory Outstanding | 229.22 | 407.21 | 297.38 | 569.71 | 835.10 |
| Days of Payables Outstanding | 640.62 | 1398.29 | 1040.17 | 463.39 | 400.75 |
| Operating Cycle | 254.74 | 454.93 | 342.69 | 585.58 | 862.98 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.68 | -3.35 | -2.15 | -1.93 | 0.22 |
| Free Cash Flow Per Share | -2.00 | -3.65 | -2.35 | -2.08 | 0.09 |
| Dividend Paid and CapEx Coverage Ratio | -5.22 | -11.06 | -10.98 | -13.65 | 1.72 |
| Capital Expenditure Coverage Ratio | -5.22 | -11.06 | -10.98 | -13.65 | 1.72 |
| Operating Cash Flow Coverage Ratio | -0.10 | -0.35 | -0.21 | -0.20 | 0.02 |
| Operating Cash Flow to Sales Ratio | -0.28 | -0.71 | -0.39 | -0.47 | 0.04 |
| Free Cash Flow Yield | -2.53% | -10.45% | -4.64% | -5.50% | 0.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -33.24 | -11.50 | -19.75 | -19.86 | -150.06 |
| Price-to-Sales (P/S) Ratio | 13.41 | 7.41 | 9.18 | 9.12 | 5.29 |
| Price-to-Book (P/B) Ratio | 25.88 | 8.88 | 18.71 | 9.35 | 5.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -39.55 | -9.57 | -21.56 | -18.19 | 332.71 |
| Price-to-Operating Cash Flow Ratio | -47.13 | -10.43 | -23.53 | -19.53 | 139.33 |
| Price-to-Earnings Growth (PEG) Ratio | 1.53 | -0.61 | -0.57 | -0.02 | 1.60 |
| Enterprise Value Multiple | -52.41 | -18.10 | -35.14 | -28.32 | -900.76 |
| Enterprise Value | 14.90B | 6.40B | 8.29B | 6.45B | 4.67B |
| EV to EBITDA | -52.41 | -18.10 | -35.14 | -28.32 | -900.76 |
| EV to Sales | 15.78 | 9.08 | 10.52 | 10.98 | 5.77 |
| EV to Free Cash Flow | -46.56 | -11.72 | -24.70 | -21.90 | 362.31 |
| EV to Operating Cash Flow | -55.48 | -12.78 | -26.95 | -23.51 | 151.73 |
| Tangible Book Value Per Share | 3.06 | 3.94 | 2.70 | 4.04 | 5.27 |
| Shareholders’ Equity Per Share | 3.06 | 3.94 | 2.70 | 4.04 | 5.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.01 | -0.10 | -0.05 | 0.02 |
| Revenue Per Share | 5.90 | 4.72 | 5.51 | 4.14 | 5.75 |
| Net Income Per Share | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 |
| Tax Burden | 1.00 | 0.99 | 1.10 | 1.05 | 0.98 |
| Interest Burden | 1.24 | 1.22 | 1.29 | 1.03 | 1.18 |
| Research & Development to Revenue | 0.97 | 1.28 | 1.14 | 1.42 | 0.79 |
| SG&A to Revenue | 0.42 | 0.38 | 0.30 | 0.26 | 0.21 |
| Stock-Based Compensation to Revenue | 0.14 | 0.18 | 0.13 | 0.17 | 0.15 |
| Income Quality | 0.70 | 1.10 | 0.84 | 1.02 | -1.08 |
Currency in USD